Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

To the Editor The recent analysis by Torga and Pienta attempted to evaluate 2 liquid biopsy test platforms (Guardant360 and PlasmaSELECT) and found "low congruence for the same patient-paired samples." However, having reanalyzed their available data, we conclude that the authors inappropriately performed a qualitative comparison of 2 quantitative tests with different reporting standards, resulting in a misrepresentation of the underlying data and misleading conclusions. Correcting for these issues, we instead find 91% patient-level concordance between the 2 tests and 100% concordance for results associated with indicated therapies.

https://ift.tt/2JBET1L